HotSpot Therapeutics is targeting nature's regulatory mechanisms to create allosteric medicines that exhibit high precision and potency. HotSpot's proprietary SpotFinder technology platform is the first and only technology platform to systematically identify and target 'regulatory hotspots'; a unique family of allosteric sites used by nature to regulate protein function. Using bespoke chemistry approaches, HotSpot is developing a pipeline of first-in-class medicines for treatment of serious autoimmune and metabolic diseases. The company has identified over 100 regulatory hotspots across a range of proteins and pathways. HotSpot's lead compounds include the first and only allosteric inhibitors to target PKC-theta, for autoimmune diseases, and S6 kinase, an immunometabolic enzyme involved in the regulation of hepatic insulin sensitivity and mitochondrial function - an important new target for NASH and metabolic diseases.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
07/17/18	$45,000,000	Series A	Atlas Venture Sofinnova Partners	undisclosed
05/21/20	$65,000,000	Series B	Atlas Venture Brace Pharma MRL Ventures Fund S.R. One Sofinnova Partners Solasta Ventures Tekla Capital Management	undisclosed
11/29/21	$100,000,000	Series C	Atlas Venture B Capital Group CaaS Capital Management LSP Monashee Investment Management MRL Ventures Fund Pavilion Capital Pivotal bioVenture Partners Revelation Partners Sofinnova Partners SR One Tekla Capital Management	undisclosed